Every 8-K that LIFELOC TECHNOLOGIES INC (LCTC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LCTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LCTC filings page.
Lifeloc Technologies, Inc. (LCTC) will participate in the virtual Lytham Partners Fall 2026 Investor Conference on September 29–30, 2026. Its webcast presentation is scheduled for September 29 at 2:45 p.m. ET, and one-on-one meetings with investors are available during the event by registration. The webcast will be available for replay following the event.
Management will provide background on Lifeloc’s breath alcohol testing business and discuss the status of its SpinDetect™ Analyzer project, described as new product development addressing market needs for rapid drug testing.
Lifeloc Technologies, Inc. reported stronger results for the quarter ended June 30, 2026. Net revenue was $2.445 million, up from $2.219 million a year earlier, and the net loss narrowed to $(134) thousand, or $(0.05) per diluted share, from $(394) thousand, or $(0.14) per share.
Gross margin improved to 45% from 42%, helped by price increases and favorable product mix, while research and development spending remained elevated at $560 thousand, largely for the SpinDetect™ analyzer. The company advanced SpinDetect development and is targeting a limited commercial launch of its oral-fluid drug analyzer in Q1 2027. During the quarter, Lifeloc also secured a $500,000 related-party term loan at 10.5% interest, secured by all company assets.
Lifeloc Technologies is advancing its SpinDetect™ Centrifugal Drug Analyzer from development into validation and early production. The company has completed production tooling for SpinDetect consumable disks, produced and tested first-article disks, made minor mold fixes, and commissioned a cleanroom with an automated reagent-dispensing robot.
Lifeloc plans a staged rollout, first targeting U.S. forensic and certain international markets, with U.S. workplace use following FDA clearance. The initial product will be a qualitative pass/fail delta-9-THC test, with quantitative and multi-drug panels to follow. The SpinDetect reader is expected to list at about $7,495 in the U.S.
Management highlights the system’s focus on measuring psychoactive delta-9-THC separately from inactive metabolites, which they view as a competitive differentiator for roadside and workplace testing. The company is also investing in its core breath alcohol L-series platform, including an OIML-variant of the LX9 device to broaden international reach and improve manufacturing costs.
Lifeloc Technologies, Inc. reported that Assure CPA, LLC resigned as its independent registered public accounting firm on June 3, 2026, after selling substantially all of its assets to Sadler, Gibb & Associates, LLC and ceasing public accounting operations. Assure’s audit reports for 2024 and 2025 contained no adverse opinions, and the company reports no disagreements or reportable events under Regulation S-K.
The company also summarized results of its June 3, 2026 annual meeting. Shareholders elected five directors, ratified the appointment of Assure CPA as independent auditor for fiscal 2026, approved an advisory say-on-pay vote on executive compensation, and adopted Amended and Restated Articles of Incorporation.
Lifeloc Technologies reported first quarter 2026 net revenue of $2.294 million and a net loss of $152,713, or $(0.06) per diluted share. Revenue grew about 1% from the prior year period, while the loss narrowed from $292,686 as gross margin improved to 43% from 40%.
Research and development remained significant at more than 18% of revenue, largely funding the SpinDetect™ Centrifugal Drug Analyzer. The company completed disk production tooling and received first article disks, described as the last enabling step before beta testing. Cash stood at $569,330 as of March 31, 2026, with total assets of $6.74 million.
In May 2026, Lifeloc closed a $500,000 loan from its Chairman and CFO at 10.5% interest, adjustable with prime, with interest-only payments in 2026 and a five-year repayment schedule and no prepayment penalty.
Lifeloc Technologies, Inc. entered into a related-party loan transaction with its Chief Financial Officer and Chairman, Vern Kornelsen. The company issued a $500,000 Promissory Note dated May 1, 2026 to fund continued development of its SpinDetect™ product.
The Note carries an initial interest rate of 10.5% per annum, with interest-only payments through December 31, 2026. Starting January 31, 2027, it converts to sixty equal monthly payments of principal and interest, with final maturity on December 31, 2031, and an interest rate that may increase with changes in the prime rate.
The Note may be prepaid at any time without penalty and is secured by a Deed of Trust on Lifeloc’s principal office at 12441 West 49th Avenue, Wheat Ridge, Colorado, and by a security interest in substantially all company assets, both subordinated to existing senior indebtedness to Citywide Banks.
Lifeloc Technologies reported full-year 2025 revenue of $9.027 million, up 6% from $8.538 million in 2024, as demand for its breath alcohol testing products grew modestly while gross margin held essentially flat at 40.3%.
The company recorded a net loss of $2.470 million, or $(0.90) per diluted share, compared with a net loss of $1.053 million, or $(0.41), in 2024. Management explains the wider loss mainly reflects a non-cash increase in the deferred tax valuation allowance to $1.738 million, driven by recent loss history. Excluding this accounting change, loss before taxes improved slightly to $1.311 million from $1.405 million.
Cash and cash equivalents declined to $746,001 at December 31, 2025 from $1.244 million, with operating activities using $499,319 of cash and continued investment in property and R&D equipment. Total assets were $6.69 million and stockholders' equity was $4.10 million, down from $6.23 million a year earlier.
Lifeloc Technologies, Inc. (LCTC) furnished a press release announcing operating results for the period ended September 30, 2025. The company made the release available on its website on November 12, 2025 and attached it as Exhibit 99.1.
The information was furnished rather than filed, which means it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless expressly stated.
Lifeloc Technologies (LCTC) announced a merger agreement with Electronic Systems Technology (ELST). A newly formed Lifeloc subsidiary will merge into ELST, and ELST will continue as a wholly owned subsidiary of Lifeloc. ELST shareholders will receive Lifeloc common stock based on an agreed exchange ratio, with cash paid in lieu of fractional shares.
Closing is subject to customary conditions, including ELST shareholder approval, the effectiveness of a Form S-4 registration statement for the shares to be issued, and required regulatory approvals. The agreement includes customary representations, warranties, covenants, termination rights, and conditions.
Lifeloc Technologies, Inc. filed a current report to note that on September 23, 2025 it issued a press release titled “Lifeloc to Present at Emerging Growth Conference on September 25, 2025.” The company is using this filing to formally furnish that press release to the market and to clarify that the release, and any websites linked within it, are not considered “filed” for liability purposes under the Securities Exchange Act or automatically incorporated into other securities filings.